A PROSPECTIVE COMPARATIVE OBSERVATIONAL STUDY ON SAFETY, EFFICACY AND COST EFFECTIVENESS OF INSULIN AND THEIR ANALOGUES
DOI:
https://doi.org/10.22159/ijpps.2018v10i7.21464Keywords:
Type-2 diabetes mellitus, Human insulin, Insulin analogue, Glycosylated hemoglobin, Incremental cost-effectiveness ratioAbstract
Objective: The objective of this study was to compare safety, efficacy and cost effectiveness of insulin and their analogues when compared with human insulin in patients with type-2 diabetes mellitus.
Methods: A prospective observational study was carried out in a multispecialty hospital. The inpatients and outpatients from general medicine and endocrinology departments were included in our study for a period of 6 mo. The diabetic profile such as FBS, PPBS, HbA1c and body weight of the diabetic patients at the initial visit and follow up visit was documented.
Results: This study showed a statistically significant reduction in HbA1c, PPBS, and FBS levels from the baseline in insulin analogue users. It was found that, insulin analogue with metformin showed statistical improvement (P<0.05) in FBS, PPBS, HbA1c as well as body weight and also found to be a cost-effective treatment according to Incremental cost-effectiveness ratio (ICER) decision matrix.
Conclusion: This study concluded that type 2 diabetes patients underlined with the treatment using insulin analogue showed a better glycemic control when compared to human insulin. Metformin was the better OHA option in type-2 diabetes mellitus when compared with sulphonylureas and also metformin showed less weight gain than sulphonylureas.
Downloads
References
Diana I Brixner, Carrie Mc Adam-Marx. Cost-effectiveness of insulin analogs. Am J Manag Care 2008;14:766-75.
Vasiliki Valla. Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Exp Diabetes Res 2010;10:1-14.
American Diabetes Association, diagnosis and classification of diabetes mellitus. Diabetes Care 2009;3:62-7.
Anil Kapur. Economic analysis of diabetes care. Indian J Med Res 2007;125:473-82.
Krentz AJ, Bailey CJ. Oral antidiabetic agents current role in type 2 diabetes mellitus. Drugs 2005;65:85-411.
Canadian agency for drugs and technologies in Health. Rapid-acting insulin analogues for the treatment of diabetes mellitus. Meta-analyses of Clinical Outcomes; 2008.
Sumeet R Singh, Fida Aahmad, Avatar Lal, Changhuaa Yu, Zemi Bai, Heather Bennett. Efficacy and safety of insulin analogues for the management of diabetes mellitus. A meta analysis: CMAJ 2009;180:385-97.
Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83.
Bengt Jonsson. The Economic impact of diabetes. Diabetes Care 1998;21:7-10.
Joshi S, Joshi P. A review of insulin and insulin regimens in type 2 diabetes. SA Fam Pract 2009;51:97-102.
Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26:18–24.
Marre M. Before oral agents fail the case for starting insulin early. Int J Obes Relat Metab Disord 2002;26:25-30.
Antonieta Medina Lara, Rubbben Mujica Mata, Dyfrig Hughes. Approaches to pharmcoeconomic analysis. In: Tom Walley, Alan Haycox, Angela Boland. Pharmacoeconomics. Churchill Livingstone; 2004. p. 101-25.
Chris G Cameron, Heather A Bennet. Cost effectiveness of insulin analogue. Diabetes Mellitus. CMAJ 2009:180:400-7.
American Diabetes Association. Economic costs of diabetes in the U. S. in 2002. Diabetes Care 2003;26:917-32.
Diana I Brixner, Carrie McAdam. Cost effectiveness of insulin analogues. AJMC 2008;11:766-75.
Palmer AJ, Valentine WJ, Foos V, Lurati F, Smith I, Lammmert M, Roze S. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Curr Med Res Opin 2007;23:895-901.
Lutz Heinemann. Hyppoglycemia and Insulin analogues. J Diabetes Its Complications 1999:13:105-14.
Published
How to Cite
Issue
Section
